TY - JOUR
T1 - The potential role of direct thrombin inhibitors in the prevention and treatment of venous thromboembolism
AU - Heit, John A.
N1 - Funding Information:
Funded, in part, by grants from the National Institutes of Health (HL66216, AR30582); the Centers for Disease Control and Prevention (TS306); U.S. Public Health Service; the Doris Duke Charitable Foundation Innovation in Clinical Research; AstraZeneca LP; and by Mayo Foundation.
PY - 2003/9/1
Y1 - 2003/9/1
N2 - Venous thromboembolism (VTE) is a common and potentially lethal disease that recurs frequently and is associated with long-term impairment and suffering. Despite a great deal of effort, the incidence of VTE has not changed substantially in the last 20 years. Independent risk factors include hospitalization (either for surgery or for acute medical illness), trauma, malignant neoplasm, central venous catheters or transvenous pacemakers, superficial vein thrombosis, and extremity paresis. Of these, hospitalization accounts for almost 60% of all VTE occurring in the community. Thus, universal effective prophylaxis of hospitalized patients would significantly reduce the incidence of VTE. Parenteral direct thrombin inhibitors are safe and effective for both prevention and treatment of acute VTE, and do not require laboratory monitoring or dose adjustment. Oral direct thrombin inhibitors may also be safe and effective, and offer enhanced convenience without diet or drug-drug interactions.
AB - Venous thromboembolism (VTE) is a common and potentially lethal disease that recurs frequently and is associated with long-term impairment and suffering. Despite a great deal of effort, the incidence of VTE has not changed substantially in the last 20 years. Independent risk factors include hospitalization (either for surgery or for acute medical illness), trauma, malignant neoplasm, central venous catheters or transvenous pacemakers, superficial vein thrombosis, and extremity paresis. Of these, hospitalization accounts for almost 60% of all VTE occurring in the community. Thus, universal effective prophylaxis of hospitalized patients would significantly reduce the incidence of VTE. Parenteral direct thrombin inhibitors are safe and effective for both prevention and treatment of acute VTE, and do not require laboratory monitoring or dose adjustment. Oral direct thrombin inhibitors may also be safe and effective, and offer enhanced convenience without diet or drug-drug interactions.
KW - Deep vein thrombosis
KW - Prophylaxis
KW - Pulmonary embolism
KW - Thrombin venous thromboembolism
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=0141819116&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0141819116&partnerID=8YFLogxK
U2 - 10.1378/chest.124.3_suppl.40S
DO - 10.1378/chest.124.3_suppl.40S
M3 - Article
C2 - 12970123
AN - SCOPUS:0141819116
SN - 0012-3692
VL - 124
SP - 40S-48S
JO - Chest
JF - Chest
IS - 3 SUPPL.
ER -